Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Compare long-run outcomes for index versus active strategies, emphasizing time horizons, persistence of outperformance, and practical takeaways.
27,723 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This article dives into Black Hills’ Q1 2026 earnings transcript, translating the numbers into actionable insights. L...
On May 12, 2026, the U.S. welcomed its first spot ETF tied to Hyperliquid's HYPE token. THYP opened on NASDAQ with $1...
Oil’s sharp moves in early 2026 push investors toward stock-based plays that mimic commodity exposure without futures...
As visa rules tighten, a growing share of U.S. firms with immigrant leaders are scrambling to secure continuity throu...
A tiny stock in the nuclear space could offer outsized gains if key milestones hit. Learn how to evaluate the opportu...
SpaceX aims for a record public debut valued at $1.75 trillion. History warns mega-IPOs can swing wildly in year one,...
Crypto dollars are moving from the sidelines to the heart of American politics, with record 2024 spending and a growi...
Bitwise CIO Matt Hougan frames crypto as a contrarian bet for institutional buyers, a view that comes as AI stocks su...
Arthur Hayes faces swift backlash after signaling bullish bets on several coins, only to exit large positions soon af...
AMD beats just 2030’s earnings target two years ahead as AI-driven data center growth accelerates. Here's what it mea...
RLJ Lodging Trust stages a material YTD rally as leisure and business travel rebound. This article examines drivers, ...